Corticosteroids reduce vascular ultrasound sensitivity in fast- track pathways (FTP): results from Coventry Multi-Disciplinary FTP for cranial Giant Cell Arteritis

References

• Dejaco C, Brouwer E, Mason JC, Buttgereit F, Matteson EL, Dasgupta B. Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities. Nat Rev Rheumatol 2017;13:578.
   PubMed Web of Science ®Google Scholar
• Dasgupta B, Borg FA, Hassan N, Alexander L, Barraclough K, Bourke B, et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology 2010;49:1594–7.
   PubMed Web of Science ®Google Scholar
• Soriano A, Muratore F, Pipitone N, Boiardi L, Cimino L, Salvarani C. Visual loss and other cranial ischaemic complications in giant cell arteritis. Nat Rev Rheumatol 2017;13:476.
   PubMed Web of Science ®Google Scholar
• Ninan J, Lester S, Hill C. Giant cell arteritis. Best Pract Res Clin Rheumatol 2017;30:169–88.
   Web of Science ®Google Scholar
• Frick KD. Economic impact of visual impairment and blindness in the United States. Arch Ophthalmol 2007;125:544–50.
   PubMed Web of Science ®Google Scholar
• Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al., European Vasculitis Study Group. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009;68:318–23.
   PubMed Web of Science ®Google Scholar
• Kaltsonoudis E, Pelechas E, Papoudou-Bai A, Markatseli TE, Elisaf M, Voulgari PV, et al. The impact of temporal artery biopsy for the diagnosis of giant cell arteritis in clinical practice in a tertiary university hospital. Plos One 2019;14:e0210845.
   PubMed Web of Science ®Google Scholar
• Schmidt WA, Kraft HE, Volker L, Vorpahl K, Gromnica-Ihle EJ. Colour Doppler sonography to diagnose temporal arteritis. Lancet 1995;345:866.
   PubMed Web of Science ®Google Scholar
• Bley TA, Reinhard M, Hauenstein C, Markl M, Warnatz K, Hetzel A, et al. Comparison of duplex sonography and high-resolution magnetic resonance imaging in the diagnosis of giant cell (temporal) arteritis. Arthritis Rheum 2008;58:2574–8.
   PubMed Web of Science ®Google Scholar
• Karassa FB, Matsagas MI, Schmidt WA, Ioannidis JP. Meta-analysis: test performance of ultrasonography for giant-cell arteritis. Ann Intern Med 2005;142:359–69.
   PubMed Web of Science ®Google Scholar
• Santoro L, D’Onofrio F, Bernardi S, Gremese E, Ferraccioli G, Santoliquido A. Temporal ultrasonography findings in temporal arteritis: early disappearance of halo sign after only 2 days of steroid treatment. Rheumatology 2013;52:622.
   PubMed Web of Science ®Google Scholar
• Hauenstein C, Reinhard M, Geiger J, Markl M, Hetzel A, Treszl A, et al. Effects of early corticosteroid treatment on magnetic resonance imaging and ultrasonography findings in giant cell arteritis. Rheumatology 2012;51:1999–2003.
   PubMed Web of Science ®Google Scholar
• Dubey S, Pinnell J, Tiivas C, Mehta P. Coventry fast track pathway for managing giant cell arteritis. Int J Clin Rheumatol 2020;15:21–5.
   Google Scholar
• Seeliger B, Sznajd J, Robson JC, Judge A, Craven A, Grayson PC, et al. Are the 1990 American College of Rheumatology vasculitis classification criteria still valid? Rheumatology 2017;56:1154–61.
   PubMed Web of Science ®Google Scholar
• Piegorsch WW. Sample sizes for improved binomial confidence intervals. Comput Stat Data Anal 2004;46:309–16.
   Web of Science ®Google Scholar
• Chan CCK. Steroid management in giant cell arteritis. Br J Ophthalmol 2001;85:1061–4.
   PubMed Web of Science ®Google Scholar
• Andersson R, Malmvall BE, Bengtsson BA.Long-term corticosteroid treatment in giant cell arteritis. Acta Med Scand 1986:220;465–9.
   PubMedGoogle Scholar
• Ling MHM, Tsuang PPJ. Side effects of corticosteroid therapy: psychiatric aspects. Arch Gen Psychiatry 1981;38:471–7.
   PubMed Web of Science ®Google Scholar
• Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med 2017;377:317–28.
   PubMed Web of Science ®Google Scholar
• Martínez-Taboada VM, Rodríguez-Valverde V, Carreño L, López-Longo J, Figueroa M, Belzunegui J, et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2008;67:625–30.
   PubMed Web of Science ®Google Scholar
• Manson SC, Brown RE, Cerulli A, Vidaurre CF. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir Med 2009;103:975–94.
   PubMed Web of Science ®Google Scholar
• Sarnes E, Crofford L, Watson M, Dennis G, Kan H, Bass D. Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. Clin Ther 2011;33:1413–32.
   PubMed Web of Science ®Google Scholar
• Gale S, Wilson JC, Chia J, Trinh H, Tuckwell K, Collinson N, et al. Risk associated with cumulative oral glucocorticoid use in patients with giant cell arteritis in real-world databases from the USA and UK. Rheumatol Ther 2018;5:327–40.
   PubMed Web of Science ®Google Scholar
• Yao T-C, Huang Y-W, Chang S-M, Tsai S-Y, Wu AC, Tsai H-J. Association between oral corticosteroid bursts and severe adverse events: a nationwide population-based cohort study. Ann Intern Med 2020;173:325–30.
   PubMed Web of Science ®Google Scholar
• McDonald L, Lambrelli D, Wasiak R, Ramagopalan SV. Real-world data in the United Kingdom: opportunities and challenges. BMC Med 2016;14:97.
   PubMed Web of Science ®Google Scholar
• Bartlett VL, Dhruva SS, Shah ND, Ryan P, Ross JS. Feasibility of using real-world data to replicate clinical trial evidence. JAMA Netw Open 2019;2:e1912869.
   PubMed Web of Science ®Google Scholar
• Luqmani R, Lee E, Singh S, Gillett M, Schmidt WA, Bradburn M, et al. The role of ultrasound compared to biopsy of temporal arteries in the diagnosis and treatment of giant cell arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. Health Technol Assess 2016;20:1–238.
   PubMed Web of Science ®Google Scholar
• Mackie SL, Dejaco C, Appenzeller S, Camellino D, Duftner C, Gonzalez-Chiappe S, et al. British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. Rheumatology 2020;59:e1–e23.
   PubMed Web of Science ®Google Scholar
• Arida A, Kyprianou M, Kanakis M, Sfikakis PP. The diagnostic value of ultrasonography-derived edema of the temporal artery wall in giant cell arteritis: a second meta-analysis. BMC Musculoskelet Disord 2010;11:44.
   PubMed Web of Science ®Google Scholar
• Pinnell J, Tiivas C, Perkins P, Blake T, Saravana S, Dubey S. Ultrasonography of occipital arteries to diagnose giant cell arteritis: a case series and literature review. Clin Rheumatol 2018;37:569–73.
   PubMed Web of Science ®Google Scholar
• Getting It Right First Time. Rheumatology (https://www.gettingitrightfirsttime.co.uk/medical-specialties/rheumatology/). Accessed 21 February 2022.
   Google Scholar
• Diamantopoulos AP, Haugeberg G, Lindland A, Myklebust G. The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a more effective strategy to improve clinical outcome in giant cell arteritis? Rheumatology 2016;55:66–70.
   PubMed Web of Science ®Google Scholar
• Prior JA, Ranjbar H, Belcher J, Mackie SL, Helliwell T, Liddle J, et al. Diagnostic delay for giant cell arteritis – a systematic review and meta-analysis. BMC Med 2017;15:120.
   PubMed Web of Science ®Google Scholar
• Royal College of Physicians. Diagnosis and management of giant cell arteritis. 2010 (https://www.rcplondon.ac.uk/guidelines-policy/diagnosis-and-management-giant-cell-arteritis). Accessed 7 October 2020.
   Google Scholar